1. Home
  2. BTBT vs GYRE Comparison

BTBT vs GYRE Comparison

Compare BTBT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bit Digital Inc.

BTBT

Bit Digital Inc.

HOLD

Current Price

$1.29

Market Cap

583.1M

Sector

Finance

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$5.97

Market Cap

606.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTBT
GYRE
Founded
2015
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
583.1M
606.4M
IPO Year
2017
2004

Fundamental Metrics

Financial Performance
Metric
BTBT
GYRE
Price
$1.29
$5.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$6.00
$17.00
AVG Volume (30 Days)
24.3M
60.8K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$113,560,320.00
$275,000.00
Revenue This Year
$38.96
$19.88
Revenue Next Year
$89.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.10
N/A
52 Week Low
$1.25
$5.44
52 Week High
$4.55
$9.42

Technical Indicators

Market Signals
Indicator
BTBT
GYRE
Relative Strength Index (RSI) 32.17 43.36
Support Level $1.25 $5.78
Resistance Level $2.42 $8.28
Average True Range (ATR) 0.11 0.27
MACD -0.02 -0.05
Stochastic Oscillator 9.80 15.18

Price Performance

Historical Comparison
BTBT
GYRE

About BTBT Bit Digital Inc.

Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: